Comprehensive Review: Overcoming the Biggest Challenges with Peptide and Protein Drugs
A critical review examines strategies including PEGylation, lipidation, nanoformulation, and novel delivery systems to overcome the instability, short half-life, and poor oral bioavailability of peptide drugs.
Quick Facts
What This Study Found
Current strategies including PEGylation, lipidation, nanoformulation, and advanced delivery systems can effectively address the chemical instability, short half-life, and poor bioavailability of peptide drugs.
Key Numbers
How They Did This
Comprehensive literature review of peptide drug challenges and strategic solutions across multiple domains.
Why This Research Matters
Peptide drugs are the fastest-growing drug class, but their limitations still restrict their potential. Understanding and overcoming these challenges is essential for the entire field.
The Bigger Picture
This review provides a roadmap for the peptide drug industry — showing how engineering and formulation science are systematically solving each limitation that has historically restricted peptide therapeutics.
What This Study Doesn't Tell Us
Review format — doesn't generate new data; some strategies work for specific peptides but not universally; cost and manufacturing complexity of advanced formulations.
Questions This Raises
- ?Will oral peptide delivery become routine in the next decade?
- ?Can AI-driven peptide design avoid instability problems at the molecular design stage?
Trust & Context
- Key Stat:
- 5 major challenges addressed Instability, short half-life, poor oral bioavailability, and immunogenicity solutions reviewed
- Evidence Grade:
- Comprehensive review — authoritative summary of current knowledge and strategies.
- Study Age:
- Published in 2026, providing the most current overview of peptide drug engineering.
- Original Title:
- Strategic Approaches for Overcoming Peptide and Protein Drug Limitations.
- Published In:
- The protein journal, 45(1), 8-21 (2026)
- Database ID:
- RPEP-15028
Evidence Hierarchy
Frequently Asked Questions
Why are peptide drugs so challenging to develop?
Peptides are fragile — they break down in acid, are destroyed by enzymes, are cleared quickly by kidneys, and can trigger immune reactions. Each of these problems requires specific engineering solutions.
What is PEGylation?
PEGylation attaches polyethylene glycol (PEG) chains to peptide drugs, making them larger so they are cleared more slowly and protected from enzymes. It's one of the most successful strategies for extending peptide drug half-life.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-15028APA
Cheshomi, Mahsa; Shobeiri, Nikta; Tajani, Amineh Sadat; Khameneh, Bahman. (2026). Strategic Approaches for Overcoming Peptide and Protein Drug Limitations.. The protein journal, 45(1), 8-21. https://doi.org/10.1007/s10930-025-10302-8
MLA
Cheshomi, Mahsa, et al. "Strategic Approaches for Overcoming Peptide and Protein Drug Limitations.." The protein journal, 2026. https://doi.org/10.1007/s10930-025-10302-8
RethinkPeptides
RethinkPeptides Research Database. "Strategic Approaches for Overcoming Peptide and Protein Drug..." RPEP-15028. Retrieved from https://rethinkpeptides.com/research/cheshomi-2026-strategic-approaches-for-overcoming
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.